ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15−0.03 (-2.54%)
Close on Nov 17, 2026Market cap $121.17MP/E –Yield –
ProQR Therapeutics cash
Cash and short-term investments held at the end of each period.
ProQR Therapeutics's cash was €117.13M at Jun 30, 2026. For fiscal 2025 it was €92.41M, down 38.1% from the year before. Over ten years it grew -0.3% a year on average. The highest annual figure on record is €187.52M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €92.41M | -38.1% |
| FY2024 | Dec 31, 2024 | €149.41M | +25.6% |
| FY2023 | Dec 31, 2023 | €118.93M | +25.5% |
| FY2022 | Dec 31, 2022 | €94.78M | -49.5% |
| FY2021 | Dec 31, 2021 | €187.52M | +147.3% |
| FY2020 | Dec 31, 2020 | €75.84M | -32.3% |
| FY2019 | Dec 31, 2019 | €111.95M | +6.0% |
| FY2018 | Dec 31, 2018 | €105.58M | +119.5% |
| FY2017 | Dec 31, 2017 | €48.10M | -18.8% |
| FY2016 | Dec 31, 2016 | €59.20M | -37.6% |
| FY2015 | Dec 31, 2015 | €94.87M | -15.9% |
| FY2014 | Dec 31, 2014 | €112.74M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €117.13M | -2.2% |
| Q1 FY2026 | Mar 31, 2026 | €81.09M | -38.8% |
| Q4 FY2025 | Dec 31, 2025 | €92.41M | -38.1% |
| Q3 FY2025 | Sep 30, 2025 | €106.88M | +19.6% |
| Q2 FY2025 | Jun 30, 2025 | €119.77M | +51.7% |
| Q1 FY2025 | Mar 31, 2025 | €132.41M | +54.5% |
| Q4 FY2024 | Dec 31, 2024 | €149.41M | +25.6% |
| Q3 FY2024 | Sep 30, 2024 | €89.40M | -25.8% |
| Q2 FY2024 | Jun 30, 2024 | €78.97M | -38.6% |
| Q1 FY2024 | Mar 31, 2024 | €85.71M | -38.3% |
| Q4 FY2023 | Dec 31, 2023 | €118.93M | +25.5% |
| Q3 FY2023 | Sep 30, 2023 | €120.55M | +20.0% |
| Q2 FY2023 | Jun 30, 2023 | €128.56M | -17.8% |
| Q1 FY2023 | Mar 31, 2023 | €138.99M | -17.1% |
| Q4 FY2022 | Dec 31, 2022 | €94.78M | -49.5% |
| Q3 FY2022 | Sep 30, 2022 | €100.43M | -35.7% |
| Q2 FY2022 | Jun 30, 2022 | €156.40M | +12.2% |
| Q1 FY2022 | Mar 31, 2022 | €167.61M | +146.9% |
| Q4 FY2021 | Dec 31, 2021 | €187.52M | +147.3% |
| Q3 FY2021 | Sep 30, 2021 | €156.14M | +75.7% |
| Q2 FY2021 | Jun 30, 2021 | €139.44M | +60.0% |
| Q1 FY2021 | Mar 31, 2021 | €67.88M | -30.8% |
| Q4 FY2020 | Dec 31, 2020 | €75.84M | -32.3% |
| Q3 FY2020 | Sep 30, 2020 | €88.85M | +18.8% |
| Q2 FY2020 | Jun 30, 2020 | €87.14M | +5.7% |
| Q1 FY2020 | Mar 31, 2020 | €98.06M | +4.2% |
| Q4 FY2019 | Dec 31, 2019 | €111.95M | +6.0% |
| Q3 FY2019 | Sep 30, 2019 | €74.79M | -34.2% |
| Q2 FY2019 | Jun 30, 2019 | €82.46M | +150.1% |
| Q1 FY2019 | Mar 31, 2019 | €94.08M | +147.6% |
| Q4 FY2018 | Dec 31, 2018 | €105.58M | +119.5% |
| Q3 FY2018 | Sep 30, 2018 | €113.72M | +168.7% |
| Q2 FY2018 | Jun 30, 2018 | €32.97M | -36.7% |
| Q1 FY2018 | Mar 31, 2018 | €38.00M | -35.8% |
| Q4 FY2017 | Dec 31, 2017 | €48.10M | -49.3% |
| Q2 FY2017 | Jun 30, 2017 | €42.32M | -62.5% |
| Q1 FY2017 | Mar 31, 2017 | €52.11M | – |
| Q4 FY2016 | Dec 31, 2016 | €59.20M | – |
| Q4 FY2015 | Dec 31, 2015 | €94.87M | – |
| Q4 FY2014 | Dec 31, 2014 | €112.74M | – |
See a number that looks wrong?